Strategic Partnerships Transform Gene Therapy Manufacturing for Rare Diseases as Market Reaches $11.4 Billion
Key Insights
The gene therapy market for rare diseases (search) has reached $11.4 billion in 2025 and is projected to grow at 20% CAGR to $58.87 billion by 2034, driven by strategic partnerships between biotechs and CDMOs.
Contract Development and Manufacturing Organizations now capture over 87.8% of the cell and gene therapy manufacturing market share, with companies like Viralgen (search) and Catalent enabling scalable production for ultra-rare disease treatments.
Patient-driven initiatives and caregiver-led collaborations are accelerating development timelines from years to six months through platform-based approaches and shared resources.
The gene therapy landscape for rare diseases (search) is experiencing unprecedented transformation, with strategic partnerships between biotechnology companies and contract manufacturers driving scalability solutions that were previously unattainable. The global gene therapy market has reached $11.4 billion in 2025 and is projected to grow at a 20% compound annual growth rate, reaching $58.87 billion by 2034.
Manufacturing Partnerships Address Critical Scalability Challenges
Contract Development and Manufacturing Organizations (CDMOs) have emerged as essential partners in scaling gene therapy production, now capturing over 87.8% of the cell and gene therapy manufacturing market share by 2035. The Orphan Therapeutics Accelerator (search) (OTXL) partnered with Viralgen (search), a CDMO specializing in AAV (Adeno-Associated Virus) vectors, to enhance manufacturing for ultra-rare disease therapies. Viralgen's Pro10™ suspension platform supports programs from preclinical stages to commercial readiness, addressing key bottlenecks in scalability.
GenSight Biologics' collaboration with Catalent, Inc., exemplifies successful manufacturing partnerships. Together, they produced LUMEVOQ® (GS010), a gene therapy for Leber Hereditary Optic Neuropathy (search) (LHON). Catalent's upstream manufacturing expertise enabled production of a safe drug batch for clinical use in 2024 and supports global Phase III trials by 2026.
Patient-Driven Innovation Accelerates Development Timelines
Patient advocacy and caregiver-led initiatives are reshaping development paradigms. Terry Pirovolakis, whose son was diagnosed with SPG50 (search), partnered with biomedical experts to develop Melpida, a gene therapy administered within 36 months of diagnosis. This case demonstrates how caregiver-led collaborations can accelerate timelines and reduce costs through shared resources and preclinical expertise.
The 2025 scientific exchange co-hosted by the Alliance for Regenerative Medicine (search) and Danaher Corporation (search) highlighted platform-based approaches to gene editing, aiming to reduce development timelines from years to six months by standardizing delivery vehicles and quality control. These platforms are particularly critical for rare diseases (search), where small patient populations demand efficient, reusable processes.
Small Biotechs Drive Innovation Through Agility
Small biotechnology companies are playing a pivotal role in advancing treatments for rare diseases (search), leveraging their unique advantages over larger pharmaceutical firms. According to Dan Williams, PhD, CEO of SynaptixBio (search), "small biotechs ... are able to move things forward ... [and] make decisions extremely quickly," allowing them to respond rapidly to new data and research opportunities.
Williams notes that "about 80% of rare diseases (search) are genetic," highlighting the impact of recent advances in genome sequencing on diagnostics and drug development. Over the past decade, collaborations with academic institutions, such as the Children's Hospital of Philadelphia, have deepened understanding of genetic components, accelerating the path from discovery to clinical trials.
Market Growth Drives Investment Despite Challenges
The rare disease therapy market specifically is expected to expand from $9.74 billion in 2025 to $24.34 billion by 2030, driven by regulatory approvals and technological advancements. The global cell and gene therapy manufacturing market, valued at $25.03 billion in 2025, is projected to reach $117.46 billion by 2034.
However, significant challenges remain. Developing rare disease therapies involves high fixed costs, often exceeding $266,000 per patient annually, and limited opportunities for label expansion. Despite these hurdles, venture capital funding for gene therapy startups is projected to exceed $15 billion in 2024, while large pharma companies are allocating $500 million annually to CDMO partnerships.
Technology and Automation Drive Future Growth
The industry is adopting innovative solutions to address persistent challenges. Single-use technologies are projected to dominate 80% of new bioreactor installations in 2024, reducing contamination risks and operational costs. AI/ML optimization is being implemented across manufacturing processes, with 20 new facilities expected to adopt these technologies by 2025.
The American Society of Gene and Cell Therapy (ASGCT) is advocating for value-based contracts and real-world evidence (RWE) to expedite FDA approvals, while automation and decentralized production hubs emerge as long-term solutions for scaling access to rare disease treatments.